Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results. [electronic resource]
Producer: 19990811Description: 403-11 p. digitalISSN:- 0923-7534
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Biomarkers, Tumor -- analysis
- Bone Neoplasms -- secondary
- Breast Neoplasms -- diagnosis
- Disease-Free Survival
- Dose-Response Relationship, Drug
- Doxorubicin -- administration & dosage
- Drug Administration Schedule
- Female
- Follow-Up Studies
- Heart Diseases -- chemically induced
- Humans
- Infusions, Intravenous
- Lung Neoplasms -- secondary
- Middle Aged
- Neoplasm Metastasis
- Paclitaxel -- administration & dosage
- Severity of Illness Index
- Soft Tissue Neoplasms -- secondary
- Survival Rate
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.